Minetta C. Liu

Jan 6, 2025 | nature.com | Amy H. Comander |Steven J Isakoff |Beverly Moy |Seth A. Wander |Minetta C. Liu |Leif W. Ellisen

AbstractOptimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules.

Nov 6, 2024 | cell.com | Michael Campbell |Denise Wolf |Christina Yau |Lamorna Brown-Swigart |Isela R. Gallagher |Zelos Zhu | +20 more

ResultsA total of 69 HER2− patients (40 HR+HER2− and 29 TN) were randomized to receive 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by anthracycline chemotherapy (Pembro+T → AC). In addition, there were 181 HER2− patients (96 HR+HER2− and 85 TN) randomized to the standard neoadjuvant chemotherapy control group (T → AC). We utilized three assay platforms to characterize the tumor immune microenvironment in these patients (Figure 1).

Sep 30, 2024 | nature.com | Minetta C. Liu

AbstractApproximately 15% of colorectal cancers (CRCs) are associated with germline mutations. There is increasing adoption of DNA-based assays for molecular residual disease (MRD) and growing evidence supporting its clinical utility, particularly for CRC by oncologists in the U.S. We assessed the uptake of germline multi-gene panel testing (MGPT) for hereditary cancer in CRC patients receiving MRD analyses in community oncology settings.

Sep 16, 2024 | nature.com | Yoshiaki Nakamura |Jun Watanabe |Naoya Akazawa |Kozo Kataoka |Yoshinori Kagawa |Kun-Huei Yeh | +10 more

AbstractThe interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC).

Apr 18, 2023 | nature.com | Xue Wang |David Hillman |Heikki Joensuu |Judy Boughey |Minetta C. Liu |James Ingle | +1 more

This study was conducted in accordance with recognized ethical guidelines, including the U.S. Common Rule. The FinXX study was approved by an Institutional Review Board at the Helsinki University Hospital (approvals 264/13/03/02/2014 and HUS/903/2017). The patients who participated in the FinXX trial (NCT00114816) signed a written informed consent to the trial participation and consent to allow the use of their tumor tissue for FinXX trial-related research purposes.